There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Perrigo Company (PRGO – Research Report), FibroGen (FGEN – Research Report) and Disc Medicine (IRON – Research Report) with bullish sentiments.
Perrigo Company (PRGO)
In a report released yesterday, Elliot Wilbur from Raymond James maintained a Buy rating on Perrigo Company. The company’s shares closed last Monday at $36.34.
According to TipRanks.com, Wilbur has 0 stars on 0-5 stars ranking scale with an average return of
Perrigo Company has an analyst consensus of Moderate Buy, with a price target consensus of $45.00.
See the top stocks recommended by analysts >>
FibroGen (FGEN)
Raymond James analyst Danielle Brill reiterated a Buy rating on FibroGen yesterday and set a price target of $35.00. The company’s shares closed last Monday at $22.51, close to its 52-week high of $24.58.
According to TipRanks.com, Brill is a 5-star analyst with an average return of
Currently, the analyst consensus on FibroGen is a Moderate Buy with an average price target of $26.00.
Disc Medicine (IRON)
SVB Securities analyst Thomas Smith initiated coverage with a Buy rating on Disc Medicine today and set a price target of $36.00. The company’s shares closed last Monday at $24.39.
According to TipRanks.com, Smith is a 5-star analyst with an average return of
Currently, the analyst consensus on Disc Medicine is a Moderate Buy with an average price target of $33.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PRGO:
